EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

A Comprehensive Systematic Review of the Role of Semaglutide Anti-Obesity Therapy in Multiple Metabolic Diseases: A Systematic Review of Randomized Controlled Trials and Primary Studies

Jeffy Marta

The International Journal of Medical Science and Health Research · 16.08.2026 · 48 (5) · 562-666

DOI: 10.70070/wcwp4h85 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The International Journal of Medical Science and Health Research, online erschienen am 16.08.2026. Verfasst von Jeffy Marta. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Obesity constitutes the pathophysiological hub of interconnected metabolic diseases including type 2 diabetes mellitus (T2DM), atherosclerotic cardiovascular disease (ASCVD), heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), metabolic dysfunction-associated steatohepatitis (MASH) and peripheral artery disease (PAD). Semaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), has been evaluated across all these domains. This systematic review synthesised primary evidence on semaglutide across multiple metabolic diseases to determine consistency of benefit across organ systems.

Methods

The study strictly adhered to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020 guidelines. Eligible designs comprised randomized controlled trials and observational studies evaluating semaglutide in obesity or obesity-related metabolic disease. Systematic reviews were excluded from primary tabulation but retained as contextual comparators. Two reviewers independently screened, extracted data and appraised risk of bias using Cochrane RoB 2 and ROBINS-I; certainty was graded with GRADE. Synthesis was narrative and semi-quantitative by outcome domain.

Results

Twenty-seven primary studies (24 RCTs, 3 observational cohorts) encompassing >180,000 participants across 15 outcome domains were included. Semaglutide 2.4 mg weekly produced mean weight reductions of -14.9% to -16.0% versus -2.4% to -5.7% with placebo (all P

Zitieren

APA

Marta, J. (2026). A Comprehensive Systematic Review of the Role of Semaglutide Anti-Obesity Therapy in Multiple Metabolic Diseases: A Systematic Review of Randomized Controlled Trials and Primary Studies. The International Journal of Medical Science and Health Research, 48(5), 562-666. https://doi.org/10.70070/wcwp4h85

Vancouver

Marta J. A Comprehensive Systematic Review of the Role of Semaglutide Anti-Obesity Therapy in Multiple Metabolic Diseases: A Systematic Review of Randomized Controlled Trials and Primary Studies. The International Journal of Medical Science and Health Research. 2026;48(5):562-666. doi:10.70070/wcwp4h85

BibTeX
@article{Marta2026,
  author = {Marta, Jeffy},
  title = {A Comprehensive Systematic Review of the Role of Semaglutide Anti-Obesity Therapy in Multiple Metabolic Diseases: A Systematic Review of Randomized Controlled Trials and Primary Studies},
  journal = {The International Journal of Medical Science and Health Research},
  year = {2026},
  volume = {48},
  number = {5},
  pages = {562--666},
  doi = {10.70070/wcwp4h85}
}
Kostenlos starten →